.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,338,489

« Back to Dashboard
Patent 8,338,489 protects HEMANGEOL and is included in one NDA.

This patent has thirty-three patent family members in twenty-seven countries.

Summary for Patent: 8,338,489

Title:Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Abstract: The present disclosure relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present disclosure provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.
Inventor(s): Leaute-Labreze; Christine (Le Haillan, FR), Dumas De La Roque; Eric (Villenave d'Ornon, FR), Taieb; Alain (Bordeaux, FR), Thambo; Jean-Beno t (Bordeaux, FR)
Assignee: Universite Victor Segalen--Bordeaux 2 (Bordeaux Cedex, FR)
Application Number:12/599,266
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Basic materials chemistry
Back Citations: 14th percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pierre Fabre Derma
HEMANGEOL
propranolol hydrochloride
SOLUTION;ORAL205410-001Mar 14, 2014RXYes8,338,489► subscribe METHOD TO TREAT HEMANGIOMA.
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,338,489

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
07291273Oct 19, 2007
PCT Information
PCT FiledOctober 16, 2008PCT Application Number:PCT/IB2008/002746
PCT Publication Date:April 23, 2009PCT Publication Number: WO2009/050567

Non-Orange Book Patents for Patent: 8,338,489

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,987,262Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas► subscribe
9,173,858Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,338,489

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina068927► subscribe
Austria512661► subscribe
Australia2008313405► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc